Acting on melatonergic receptors: a milestone in the treatment of depression

Proceedings of a satellite symposium held on the occasion of the 18th ECNP congress,
Amsterdam, October 22–26, 2005

GUEST EDITOR:
Stuart A. Montgomery

Published with the help of an unrestricted educational grant from Servier

CONTENTS

S1 Why do we need new and better antidepressants?
   Stuart A. Montgomery

S11 Biological rhythm disturbances in mood disorders
   Anna Wirz-Justice

S17 Pharmacology of a new antidepressant: benefit of the implication of the melatonergic system
   Eberhard Fuchs, Maria Simon and Barthel Schmelting

S21 Clinical efficacy of agomelatine in depression: the evidence
   J.A. Den Boer, F.J. Bosker and Y. Meesters

S25 Sleep disturbances and depression: a challenge for antidepressants
   Raymond W. Lam

S31 Efficacy and tolerance profile of agomelatine and practical use in depressed patients
   Frédéric Rouillon

Subscribing organizations are encouraged to copy and distribute
the table of contents printed in this issue for internal, non-commercial purposes

Visit the International Clinical Psychopharmacology website at
www.intclinpsychopharm.com